๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest

Search Results

Found 8 results for "canada" across articles, medicines, trials, companies and the glossary

Ireland's Biopharma Manufacturing Hub: A Master Guide to Tax, Talent, CDMO Sourcing, and Regulatory Excellence
Biotechnology
Ireland's Biopharma Manufacturing Hub: A Master Guide to Tax, Talent, CDMO Sourcing, and Regulatory Excellence
An in-depth analysis of Ireland's evolution into Europe's second-largest exporter of medicinal products. Discover how a 12.5% tax structure, NIBRT bioprocessing excellence, HPRA regulatory trust, and a thriving CDMO ecosystem make Ireland the premier location for global drug production.
21 Jul 2026
Ireland Family Reunification 2026: The Complete Guide to Financial Thresholds, Waiting Periods, How to Apply, and What Every Sponsor Must Know
Regulatory Affairs
Ireland Family Reunification 2026: The Complete Guide to Financial Thresholds, Waiting Periods, How to Apply, and What Every Sponsor Must Know
A detailed, practical guide to Ireland's Non-EEA Family Reunification Policy as updated in 2026. Covers the new financial thresholds for all sponsor categories, country-specific waiting periods, step-by-step application process, and a comprehensive pre-application checklist - essential reading for pharmacists, healthcare workers, and life science professionals bringing family to Ireland.
27 Jun 2026
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Irelandโ€™s Life Sciences Sector
Pharmaceutical
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Irelandโ€™s Life Sciences Sector
An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.
22 Jun 2026
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
Regulatory Affairs
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.
21 Jun 2026
Jazz Pharmaceuticals Strikes Strategic $820M Research Deal with AbCellera for Next-Gen T-Cell Engaging Antibodies
Industry
Jazz Pharmaceuticals Strikes Strategic $820M Research Deal with AbCellera for Next-Gen T-Cell Engaging Antibodies
Discover how Jazz Pharmaceuticals and AbCellera are joining forces in a high-stakes, $820M biopharma collaboration to pioneer next-generation T-cell engaging (TCE) multispecific antibodies targeting gastrointestinal cancers and challenging solid tumors.
18 Jun 2026
Avectas: Engineering the Future of Cell Therapy Manufacturing
Pharmaceutical
Avectas: Engineering the Future of Cell Therapy Manufacturing
Recognizing the critical industry bottleneck in scalable cell therapy production, Avectas has announced a landmark collaboration with CCRM and OmniaBio to evaluate its innovative manufacturing platform.
16 Jun 2026
Navigating Challenges in Oncology: Jazz Pharmaceuticals and PharmaMar Stay Committed Despite Phase 3 Setback
Clinical Trials
Navigating Challenges in Oncology: Jazz Pharmaceuticals and PharmaMar Stay Committed Despite Phase 3 Setback
In the rigorous and highly demanding landscape of oncology research, scientific progress is often non-linear. Recently, Jazz Pharmaceuticals and its partner PharmaMar announced that their Phase 3 trial evaluating Zepzelca did not meet its primary endpoint.
16 Jun 2026
Prime Minister Carney Expands Canada-Ireland Partnership in Science, Technology, and Pharma
Industry
Prime Minister Carney Expands Canada-Ireland Partnership in Science, Technology, and Pharma
Canadian Prime Minister Mark Carney's landmark visit to Ireland strengthens bilateral cooperation in artificial intelligence, biomanufacturing, and resilient health systems, highlighting massive new investments in the life science sector.
15 Jun 2026